Dianqin Sun1, Maomao Cao1, He Li1, Jiansong Ren1, Jufang Shi1, Ni Li1, Wanqing Chen2. 1. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China. 2. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China. chenwq@cicams.ac.cn.
Abstract
BACKGROUND: Although previous studies have shown a decreased incidence of prostate cancer in men with HIV/AIDS, the consensus has not been reached. Our aim is to conduct a systematic review and meta-analysis to assess the risk of prostate cancer among people with HIV/AIDS. METHODS: We systematically searched PubMed, Web of Science, Embase, and Cochrane Library until March 2020. Cohort studies were included if they compared the prostate cancer risk between people with HIV/AIDS and uninfected controls or the general population. The summary standardized incidence ratio (SIR) and 95% confidence interval (CI) were calculated using a random-effects model. RESULTS: A total of 27 studies were included for analysis, with more than 2780 males with HIV/AIDS developing prostate cancer. The results showed that HIV infection was associated with a decreased risk of prostate cancer incidence (SIR, 0.76; 95% CI, 0.64-0.91; P = 0.003), with significant heterogeneity (P < 0.001; I2 = 91.6%). A range of sensitivity analyzes did not significantly change the results. CONCLUSIONS: Our study shows that people with HIV/AIDS have a lower incidence of prostate cancer compared with the general population. However, significant heterogeneity exists among the included studies. Further prospective studies with better designs are needed to elucidate the association between HIV infection and prostate cancer.
BACKGROUND: Although previous studies have shown a decreased incidence of prostate cancer in men with HIV/AIDS, the consensus has not been reached. Our aim is to conduct a systematic review and meta-analysis to assess the risk of prostate cancer among people with HIV/AIDS. METHODS: We systematically searched PubMed, Web of Science, Embase, and Cochrane Library until March 2020. Cohort studies were included if they compared the prostate cancer risk between people with HIV/AIDS and uninfected controls or the general population. The summary standardized incidence ratio (SIR) and 95% confidence interval (CI) were calculated using a random-effects model. RESULTS: A total of 27 studies were included for analysis, with more than 2780 males with HIV/AIDS developing prostate cancer. The results showed that HIV infection was associated with a decreased risk of prostate cancer incidence (SIR, 0.76; 95% CI, 0.64-0.91; P = 0.003), with significant heterogeneity (P < 0.001; I2 = 91.6%). A range of sensitivity analyzes did not significantly change the results. CONCLUSIONS: Our study shows that people with HIV/AIDS have a lower incidence of prostate cancer compared with the general population. However, significant heterogeneity exists among the included studies. Further prospective studies with better designs are needed to elucidate the association between HIV infection and prostate cancer.
Authors: Hilary A Robbins; Ruth M Pfeiffer; Meredith S Shiels; Jianmin Li; H Irene Hall; Eric A Engels Journal: J Natl Cancer Inst Date: 2015-02-06 Impact factor: 13.506
Authors: Michael J Silverberg; Bryan Lau; Chad J Achenbach; Yuezhou Jing; Keri N Althoff; Gypsyamber D'Souza; Eric A Engels; Nancy A Hessol; John T Brooks; Ann N Burchell; M John Gill; James J Goedert; Robert Hogg; Michael A Horberg; Gregory D Kirk; Mari M Kitahata; Philip T Korthuis; William C Mathews; Angel Mayor; Sharada P Modur; Sonia Napravnik; Richard M Novak; Pragna Patel; Anita R Rachlis; Timothy R Sterling; James H Willig; Amy C Justice; Richard D Moore; Robert Dubrow Journal: Ann Intern Med Date: 2015-10-06 Impact factor: 25.391
Authors: Lesley S Park; Janet P Tate; Keith Sigel; David Rimland; Kristina Crothers; Cynthia Gibert; Maria C Rodriguez-Barradas; Matthew Bidwell Goetz; Roger J Bedimo; Sheldon T Brown; Amy C Justice; Robert Dubrow Journal: AIDS Date: 2016-07-17 Impact factor: 4.177
Authors: Pragna Patel; Debra L Hanson; Patrick S Sullivan; Richard M Novak; Anne C Moorman; Tony C Tong; Scott D Holmberg; John T Brooks Journal: Ann Intern Med Date: 2008-05-20 Impact factor: 25.391
Authors: Dorothea M Wunder; Nick A Bersinger; Christoph A Fux; Nicolas J Mueller; Bernard Hirschel; Matthias Cavassini; Luigia Elzi; Patrick Schmid; Enos Bernasconi; Bruno Mueller; Hansjakob Furrer Journal: Antivir Ther Date: 2007
Authors: L Dal Maso; J Polesel; D Serraino; M Lise; P Piselli; F Falcini; A Russo; T Intrieri; M Vercelli; P Zambon; G Tagliabue; R Zanetti; M Federico; R M Limina; L Mangone; V De Lisi; F Stracci; S Ferretti; S Piffer; M Budroni; A Donato; A Giacomin; F Bellù; M Fusco; A Madeddu; S Vitarelli; R Tessandori; R Tumino; B Suligoi; S Franceschi Journal: Br J Cancer Date: 2009-02-17 Impact factor: 7.640
Authors: Witness Mapanga; Shane A Norris; Ashleigh Craig; Yoanna Pumpalova; Oluwatosin A Ayeni; Wenlong Carl Chen; Judith S Jacobson; Alfred I Neugut; Mazvita Muchengeti; Audrey Pentz; Sean Doherty; Shauli Minkowitz; Mohammed Haffejee; Tim Rebbeck; Maureen Joffe Journal: PLoS One Date: 2022-10-18 Impact factor: 3.752